Therapeutic strategies for the treatment of dyspepsia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 15, 2010, Pages 2517-2525

  Kandulski, Arne ^a   Venerito, Marino ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Antidepressants; Functional dyspepsia; H. pylori; Herbal preparations; Placebo; Prokinetics; Proton pump inhibitors; ROME III criteria; Therapy

Indexed keywords

ACOTIAMIDE; AMITRIPTYLINE; ARTICHOKE LEAF EXTRACT; BUSPIRONE; CAPSAICIN; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IBEROGAST; ITOPRIDE; KAMPO; MIRTAZAPINE; MITEMCINAL; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PLACEBO; PLANT EXTRACT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; RIKKUNNSHI TO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STW 5; TEGASEROD; TZP 101; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; BURNING SENSATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; ECHOGRAPHY; EPIGASTRIC PAIN; ERADICATION THERAPY; ESOPHAGOGASTRODUODENOSCOPY; FUNCTIONAL DYSPEPSIA; GASTROINTESTINAL MOTILITY DISORDER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HERBAL MEDICINE; HUMAN; HYPNOSIS; INTESTINE ENDOSCOPY; LABORATORY TEST; MOLECULAR MECHANICS; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PLACEBO EFFECT; PRACTICE GUIDELINE; PSYCHOTHERAPY; REVIEW; TREATMENT RESPONSE;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MANAGEMENT; DYSPEPSIA; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77957088692     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.501794     Document Type: Review

References (102)

1. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-1268
2. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004;19:643-654
3. Quartero AO, Numans ME, Post MW, et al. One-year prognosis of primary care dyspepsia: predictive value of symptom pattern, Helicobacter pylori and GP management. Eur J Gastroenterol Hepatol 2002;14:55-60
4. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002;20:347-355
5. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479
6. Chiba N. Treat the patients main dyspepsia complaint, not the ROME criteria. Am J Gastroenterol 2004;99:1059-1062
7. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-2337
8. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003:CD001961
9. Tack J, Lee KJ. Pathophysiology and treatment of functional dyspepsia. J Clin Gastroenterol 2005;39:S211-6
10. Selgrad M, Kandulski A, Malfertheiner P. Dyspepsia and Helicobacter pylori. Dig Dis 2008;26:210-214
11. Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998;43:2028-2033
12. Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996;110:1036-1042
13. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346-1352
14. Kim DY, Delgado-Aros S, Camilleri M, et al. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 2001;96:3099-3105
15. Troncon LE, Bennett RJ, Ahluwalia NK, Thompson DG. Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients. Gut 1994;35:327-332
16. Holtmann G, Goebell H, Talley J. Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. Am J Gastroenterol 1996;91:485-491
17. Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1175-1183
18. McNamara D, Buckley M, OMorain C. Will eradication of Helicobacter pylori improve symptoms of non-ulcer dyspepsia? More studies should have been included in meta-analysis. BMJ 2000;320:1209-1210
19. OMorain C. Role of Helicobacter pylori in functional dyspepsia. World J Gastroenterol 2006;12:2677-2680
20. el-Omar E, Penman I, Ardill JE, McColl KE. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. Gut 1995;36:534-538
21. van den Elzen BD, Bennink RJ, Holman R, et al. Impaired drinking capacity in patients with functional dyspepsia: intragastric distribution and distal stomach volume. Neurogastroenterol Motil 2007;19:968-976
22. van den Elzen BD, Boeckxstaens GE. Review article: a critical view on impaired accommodation as therapeutic target for functional dyspepsia. Aliment Pharmacol Ther 2006;23:1499-1510
23. Boeckxstaens GE, Hirsch DP, van den Elzen BD, et al. Impaired drinking capacity in patients with functional dyspepsia: relationship with proximal stomach function. Gastroenterology 2001;121:1054-1063
24. Vandenberghe J, Dupont P, Van OL, et al. Regional cerebral blood flow during gastric balloon distention in functional dyspepsia. Gastroenterology 2007;132:1684-1693
25. Van OL, Dupont P, Vandenberghe J, et al. The role of somatosensory cortical regions in the processing of painful gastric fundic distension: an update of brain imaging findings. Neurogastroenterol Motil 2008;20:479-487
26. Hunt RH, Fallone C, Veldhuyzen van ZS, et al. Etiology of dyspepsia: implications for empirical therapy. Can J Gastroenterol 2002;16:635-641
27. Kleibeuker JH, Thijs JC. Functional dyspepsia. Curr Opin Gastroenterol 2004;20:546-550
28. Bytzer P, Hansen JM, Rune S, et al. Identifying responders to acid suppression in dyspepsia using a random starting day trial. Aliment Pharmacol Ther 2000;14:1485-1494
29. Madsen LG, Bytzer P. Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design. Aliment Pharmacol Ther 2004;20:365-372
30. Madsen LG, Wallin L, Bytzer P. Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial - is gastro-oesophageal reflux important? Aliment Pharmacol Ther 2004;20:423-430
31. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005;17:325-331
32. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007;13:3425-3429
33. Bernstein CN. The placebo effect for gastroenterology: tool or torment. Clin Gastroenterol Hepatol 2006;4:1302-1308
34. Talley NJ, Silverstein MD, Agreus L, et al. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998;114:582-595
35. Tytgat G, Hungin AP, Malfertheiner P, et al. Decision-making in dyspepsia: controversies in primary and secondary care. Eur J Gastroenterol Hepatol 1999;11:223-230
36. Talley NJ, Vakil N, Delaney B, et al. Management issues in dyspepsia: current consensus and controversies. Scand J Gastroenterol 2004;39:913-918
37. Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-1016
38. Malfertheiner P, Megraud F, OMorain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781 (Pubitemid 46854190)
39. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002;122:1270-1285
40. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008;336:651-654
41. Ford AC, Moayyedi P, Jarbol DE, et al. Meta-analysis: Helicobacter pyloritest and treat compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008;28:534-544
42. Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329-1337
43. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-1780
44. Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001;15:1291-1299
45. Veldhuyzen Van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005;100:1477-1488
46. Armstrong D, Veldhuyzen Van Zanten SJ, Barkun AN, et al. Heartburn-dominant, uninvestigated dyspepsia: a comparison of PPI-start and H2-RA-start management strategies in primary care - the CADET-HR Study. Aliment Pharmacol Ther 2005;21:1189-1202
47. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006:CD001960
48. Talley NJ, Vakil N, Lauritsen K, et al. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther 2007;26:673-682 (Pubitemid 47246199)
49. Barton PM, Moayyedi P, Talley NJ, et al. A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. Med Decis Making 2008;28:44-55
50. Veldhuyzen Van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-696
51. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832-840
52. Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-746
53. Moayyedi P, Soo S, Deeks J, et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003;17:1215-1227
54. Chey WD, Howden CW, Tack J, et al. Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. Dig Dis Sci 2010;55:684-697
55. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008;103:1906-1919
56. Miner PB Jr, Rodriguez-Stanley S, Proskin HM, et al. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. Curr Med Res Opin 2008;24:2159-2172
57. Yogo K, Onoma M, Ozaki K, et al. Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. Dig Dis Sci 2008;53:912-918
58. Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002;14:221-227
59. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997;280:1270-1276
60. Talley NJ, Camilleri M, Burton D, et al. Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. Aliment Pharmacol Ther 2006;24:859-867
61. Dinan TG, Mahmud N, Rathore O, et al. A double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia - are central serotoninergic responses enhanced? Aliment Pharmacol Ther 2001;15:1613-1618
62. Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008;20:1051-1059
63. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-696
64. Von AU, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;102:1268-1275
65. Braden B, Caspary W, Borner N, et al. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil 2009;21:632-8, e25
66. Melzer J, Rosch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20:1279-1287
67. Holtmann G, Adam B, Haag S, et al. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003;18:1099-1105
68. Rodriguez-Stanley S, Collings KL, Robinson M, et al. The effects of capsaicin on reflux, gastric emptying and dyspepsia. Aliment Pharmacol Ther 2000;14:129-134
69. Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. N Engl J Med 2002;346:947-948
70. Bortolotti M, Coccia G, Grossi G, Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002;16:1075-1082 (Pubitemid 34680749)
71. Suzuki H, Inadomi JM, Hibi T, et al. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:688-696
72. Jackson JL, OMalley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72
73. Choung RS, Cremonini F, Thapa P, et al. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008;20:220-227
74. Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005;21(Suppl 2):42-46
75. Gorelick AB, Koshy SS, Hooper FG, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998;275:G460-6
76. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160-165
77. Tack J, Broekaert D, Coulie B, et al. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003;17:603-608
78. Ladabaum U, Glidden D. Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol Motil 2002;14:395-402
79. Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther 2006;24:475-492
80. Haug TT, Wilhelmsen I, Svebak S, et al. Psychotherapy in functional dyspepsia. J Psychosom Res 1994;38:735-744
81. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-283
82. Calvert EL, Houghton LA, Cooper P, et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002;123:1778-1785
83. Mine K, Kanazawa F, Hosoi M, et al. Treating nonulcer dyspepsia considering both functional disorders of the digestive system and psychiatric conditions. Dig Dis Sci 1998;43:1241-1247
84. Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005:CD002301
85. Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004;99:1817-1822
86. Jarbol DE, Kragstrup J, Stovring H, et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol 2006;101:1200-1208
87. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100-2115
88. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009;29:765-773
89. Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy-an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010;31:1229-1236
90. Friesen CA, Neilan NA, Schurman JV, et al. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol 2009;9:32
91. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-1874
92. Blum AL, Talley NJ, OMorain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-1881
93. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months follow up The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999;318:833-837
94. Malfertheiner P. Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit. Eur J Gastroenterol Hepatol 2001;13(Suppl 2):S9-11
95. Koelz HR, Arnold R, Stolte M, et al. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Gut 2003;52:40-46
96. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395-1402
97. Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997;11:541-546
98. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065
99. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002;50(Suppl 4):iv36-41
100. Meineche-Schmidt V, Talley NJ, Pap A, et al. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol 1999;34:566-574
101. Peura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004;116:740-748
102. van Zanten SV, Flook N, Talley NJ, et al. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks treatment with esomeprazole: a randomized, placebo-controlled study. Aliment Pharmacol Ther 2007;26:665-672